| Why carry out this study? |
| Tiotropium/olodaterol fixed-dose combination (FDC) improves exercise capacity in patients with chronic obstructive pulmonary disease (COPD). |
| The effects of FDC, administered in a single device, on physical functioning in a real-life setting had not been fully determined. |
| What was learned from the study? |
| Self-reported physical functioning and the general condition of COPD patients treated with tiotropium/olodaterol FDC via the Respimat device improved. |
| Both improvement and satisfaction were observed across all GOLD ABCD classification groups. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.